Axcella to Report Third Quarter 2020 Financial Results and Hold Conference Call on November 12, 2020
Axcella (AXLA), a clinical-stage biotechnology firm, will report its Q3 financial results and business updates on November 12, 2020. The conference call will begin at 8:30 a.m. ET and can be accessed via telephone or through a webcast on Axcella's website. The company focuses on treating complex diseases using endogenous metabolic modulator compositions, with lead candidates targeting non-alcoholic steatohepatitis and hepatic encephalopathy. Investors are encouraged to monitor the company's website for updates and disclosures.
- Axcella is focusing on innovative treatments for complex diseases, which may attract investor interest.
- The upcoming financial results report could provide insights into potential growth and financial health.
- None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its third quarter financial results and other business updates on November 12, 2020. The company will host a conference call at 8:30 a.m. ET that morning.
The conference call webcast will be available in the Investors & News section on the company’s website at www.axcellahealth.com. To access the call via telephone, please dial (866) 652-5200 (U.S. toll free) or (412) 317-6060 (international) five minutes prior to the start time. For those unable to listen in live, a webcast archive will be available on the company’s website for 30 days following the call.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors and News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.
About Axcella
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit www.axcellahealth.com.
